TG Therapeutics Inc (NASDAQ:TGTX) has a beta value of 2.14 and has seen 0.46 million shares traded in the recent trading session. The company, currently valued at $6.06B, closed the recent trade at $38.59 per share which meant it lost -$0.84 on the day or -2.13% during that session. The TGTX stock price is -12.26% off its 52-week high price of $43.32 and 66.49% above the 52-week low of $12.93. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.37 million shares traded. The 3-month trading volume is 2.66 million shares.
The consensus among analysts is that TG Therapeutics Inc (TGTX) is Buy stock at the moment, with a recommendation rating of 1.38. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.16.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Sporting -2.13% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TGTX stock price touched $38.59 or saw a rise of 10.09%. Year-to-date, TG Therapeutics Inc shares have moved 28.21%, while the 5-day performance has seen it change -9.84%. Over the past 30 days, the shares of TG Therapeutics Inc (NASDAQ:TGTX) have changed 12.12%. Short interest in the company has seen 26.23 million shares shorted with days to cover at 7.84.
Wall Street analysts have a consensus price target for the stock at $27.5, which means that the shares’ value could drop -40.33% from the levels at last check today. The projected low price target is $27.5 while the price target rests at a high of $27.5. In that case, then, we find that the latest price level in today’s session is 28.74% off the targeted high while a plunge would see the stock lose 28.74% from the levels at last check today.
TG Therapeutics Inc (TGTX) estimates and forecasts
The company’s shares have gained 61.94% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 68.23%.
6 analysts offering their estimates for the company have set an average revenue estimate of 117.07M for the current quarter. 6 have an estimated revenue figure of 130.24M for the next ending quarter. Year-ago sales stood 63.47M and 73.47M respectively for this quarter and the next, and analysts expect sales will grow by 84.44% for the current quarter and 68.23% for the next. Earnings growth for 2025 is a modest 549.52% while over the next 5 years, the company’s earnings are expected to increase by 156.12%.
TGTX Dividends
TG Therapeutics Inc is expected to release its next earnings report on 2025-Mar-02 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
Insiders own 9.38% of the company shares, while shares held by institutions stand at 62.74% with a share float percentage of 69.23%. Investors are also buoyed by the number of investors in a company, with TG Therapeutics Inc having a total of 423.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 13.69 million shares worth more than $243.58 million. As of 2024-06-30, VANGUARD GROUP INC held 9.3645% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 11.39 million shares as of 2024-06-30. The firm’s total holdings are worth over $202.6 million and represent 7.8688% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. As of Feb 28, 2025, the former fund manager holds about 5.42% shares in the company for having 8.51 shares of worth $329.48 million while later fund manager owns 4.33 shares of worth $167.83 million as of Dec 31, 2024, which makes it owner of about 2.76% of company’s outstanding stock.
